SM Energy Company Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? SM Energy Company Common Stock trades at $38.06 (market cap $9.17B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: SM Energy Company Common Stock is far larger — about 5.1× Vir Biotechnology Inc. Common Stock's market cap, and SM Energy Company Common Stock pays a 2.28% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SM Energy Company Common Stock for 2 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| SM | VIR | |
|---|---|---|
Market Cap | $9.17B | $1.80B |
Volume | 2,026,791 | 1,782,836 |
Sector | Energy | Health |
52-Week High | $41.29 | $11.78 |
52-Week Low | $17.57 | $5.12 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $15.58B | $1.36B |
Dividend Yield | 2.28% | — |
Signals from Pluang's Aura AI — not financial advice
SM Energy (SM) trades at $38.54, up 2.26% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with a low P/E of 6.83, healthy profit margins above 19%, and positive cash flow generation. Recent analyst coverage remains overwhelmingly positive with 65% buy ratings and a $39.08 consensus target, slightly above current levels.
Outlook remains favorable given strong earnings momentum and attractive valuation metrics, though overbought RSI readings suggest near-term consolidation risk. The company's upcoming Q3 2026 earnings report on November 3rd represents the next key catalyst for price movement.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
SM Energy is an independent oil and natural gas exploration and production company. Its operations include the Permian, Maverick, Uinta, and Denver-Julesburg basins.
Read more on SM →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →